Renal Guard CEO Jim Dillon Discusses Spin Out of High Profile Reprieve Cardiovascular

Medtech Talk

English - October 15, 2018 04:00 - 32 minutes - 15.1 MB - ★★★★★ - 56 ratings
Investing Business Health & Fitness medtech medical device venture capital health care innovation cardiology start-ups orthopedics digital health fda Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Endotronix CEO Harry Rowland Knows Medtech Start-Ups Live on the Edge. How Does He Keep Balanced?

Next Episode: AdvaMed CEO Scott Whitaker Talks Mid-Terms, Device Tax and Innovative Programs for Smaller Companies

Jim Dillon, president and CEO of Renal Guard, talks about the company’s decision to create Reprieve Cardiovascular, a start-up focusing on heart failure. Reprieve raised $7 million from outside investors, including Abiomed, and counts Serial Entrepreneur Howard Levin as chief medical officer.